NeuroHealing Pharmaceuticals Initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients

Newton, Massachusetts – February 19, 2008 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the initiation of a Phase II clinical trial of NH004 for the treatment of sialorrhea (uncontrolled drooling) in Parkinson’s disease (PD) patients. The first patients have been enrolled, and dosing was initiated…

NeuroHealing Pharmaceuticals Appoints Burt Adelman, M.D., to Board of Directors

Newton, Massachusetts – January 3, 2008 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the appointment of Burt A. Adelman, M.D., to the company’s Board of Directors. Burt Adelman M.D. was most recently Executive Vice President, Portfolio Strategy at Biogen Idec, having retired from this position…

The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers for a Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients

Newton, Massachusetts – December 13, 2007 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced that the Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded the company a grant to advance the clinical development of NH004, a novel treatment for sialorrhea (uncontrolled drooling). This grant…

NeuroHealing Pharmaceuticals Presents Clinical Data for NH001 in Coma Recovery at The American Society for Experimental NeuroTherapeutics (ASENT) Annual Meeting

Newton, Mass., March 12, 2007 NeuroHealing Pharmaceuticals Inc., a a clinical stage private company developing products for individuals with chronic brain injuries, today announced that it had presented new clinical data for its coma recovery compound, NH001, at the American Society for Experimental NeuroTherapeutics (ASENT) 9th annual meeting, held in Washington, DC from March 7-10,…

NeuroHealing Pharmaceuticals CEO, Neal Farber, to Speak at The Dow Jones Venturewire Health Care Innovations 2006 Conference, The Biotech & Life Sciences Global Venture Congress 2006, and The Life Sciences Venture Summit 2006

Newton, Mass., September 12, 2006. NeuroHealing Pharmaceuticals Inc., a private company developing innovative therapeutic products for neuro- rehabilitation, today announced that its CEO Neal M. Farber, Ph.D., has accepted invitations to speak at three upcoming investor conferences. Dr. Farber will speak at the Dow Jones VentureWire Health Care Innovations conference scheduled for September 12-13 at…

Neurohealing receives FDA orphan drug designation for NH001 for the treatment of patients in a vegetative state or minimally conscious state following brain injury

Newton, Mass., May 25, 2006 NeuroHealing Pharmaceuticals, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug status to NH001 for the treatment of patients in a vegetative state or minimally conscious state for up to twelve months following a brain injury (traumatic…

Life Science Angels Invests in NeuroHealing Pharmaceuticals. Company is Preparing for Two Phase II Clinical Trials: one to Aid Patients Recovering from Coma and another to Treat Sialorrhea in Parkinson’s Disease

Palo Alto, Calif. and Newton, Mass., April 05, 2006 — PRNewswire Life Science Angels, Inc., a Bay Area healthcare angel investment group focused exclusively on early stage biotechnology and medical device companies, announced today an investment in NeuroHealing Pharmaceuticals, Inc. NeuroHealing Pharmaceuticals is a clinical stage company developing therapies to improve the neuro-rehabilitation process and…

NeuroHealing Announces Presentation of Preliminary Results of Clinical Studies of NH001 for Coma Patients at 4th World NeuroRehabilitation Congress, feb 12-16, 2006

Newton, Mass., February 10, 2006. NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announces that preliminary results from its ongoing clinical studies of NH001 for coma patients will be presented by Dr. Esteban Fridman at the 4th World Neurorehabilitation Congress to take place in Hong Kong on February 12-16,…

NeuroHealing Pharmaceuticals Announces IND Clearance for NH001 to Improve The Outcome of Patients in a Vegetative State Following a Traumatic Brain Injury

Newton, Mass., January 17, 2006 NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a 76-patients, Phase II clinical trial with NH001. The study is entitled “A Double-Blind, Placebo-Controlled, Randomized…